Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 4,860,000 shares, a drop of 6.5% from the March 31st total of 5,200,000 shares. Based on an average daily volume of 2,140,000 shares, the short-interest ratio […]
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report)‘s stock had its “outperform” rating reissued by stock analysts at William Blair in a research report issued on Friday, RTT News reports. Other analysts have also recently issued research reports about the company. Royal Bank of Canada started coverage on Fusion Pharmaceuticals in a research report on Wednesday, […]